Acquisition Strategy Revolution Medicines has been actively acquiring other companies in the biotechnology sector, such as Pharmatching GmbH and NS Healthcare. This presents a potential sales opportunity for suppliers or service providers looking to partner with a growing organization in the biotech industry.
Market Expansion Through recent mergers and acquisitions with companies like EQRx, Revolution Medicines is expanding its market presence and portfolio. This signals a growth phase and potential need for new solutions or technologies that can complement their existing offerings, creating opportunities for partnerships or collaborations.
Financial Health With a reported revenue of $50M - $100M and a funding of $324M, Revolution Medicines demonstrates financial stability and capability for strategic investments. This suggests potential opportunities for high-value partnerships with vendors or service providers offering premium products or services.
Technical Stack From Varnish to Kubernetes and Python, Revolution Medicines employs a range of technologies in their operations. Technology solution providers can leverage this information to tailor their offerings and approach the company with tech solutions that align with Revolution Medicines' existing stack.
RAS-Addicted Cancers Focus Revolution Medicines is dedicated to developing targeted therapies for RAS-addicted cancers, occupying a niche in the oncology space. This specific focus presents an opportunity for pharmaceutical companies, research institutions, or medical suppliers specializing in cancer treatment to collaborate on innovative solutions in this area.
66
977
$100M$1B
160$10M$50M
146$10M$50M
413$50M$100M
114$10M$50M
11
731$100M$1B
201$50M$100MRevolution Medicines uses 8 technology products and services including Varnish, Kubernetes, Microsoft Excel, and more. Explore Revolution Medicines's tech stack below.
| Revolution Medicines Email Formats | Percentage |
| FLast@revolutionmedicines.com | 53% |
| First@revolutionmedicines.com | 39% |
| First.Last@revolutionmedicines.com | 4% |
| FL@revolutionmedicines.com | 2% |
| FiLast@revolutionmedicines.com | 1% |
| Last@revolutionmedicines.com | 1% |
| FLast@revmed.com | 77% |
| First@revmed.com | 22% |
| Last@revmed.com | 1% |
Biotechnology ResearchCalifornia, United States501-1000 Employees
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.
Company Overview
Funding & FinancialsRevolution Medicines has raised a total of $324M of funding over 8 rounds. Their latest funding round was raised on Mar 02, 2023 in the amount of $324M.
Revolution Medicines's revenue is in the range of $50M$100M
Funding & FinancialsRevolution Medicines has raised a total of $324M of funding over 8 rounds. Their latest funding round was raised on Mar 02, 2023 in the amount of $324M.
Revolution Medicines's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com